RxDoctor Payments Data

Marc Levine, MD

Cardiovascular Disease · Boynton Beach, FLNPI 1144273400

Payments from drug & device makers

$2,511in general payments, 2019–2025

Across 120 payments — averaging $20.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$631
  • Novartis$507
  • E.r. Squibb & Sons, L.L.C.$336
  • Pfizer$287
  • Amgen$209
  • Cook Medical LLC$120
  • plus $420 from 11 others

What the payments were for

  • Food & beverage$2,49799%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,511 in reported general payments places this provider in the 40th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$108,777
Medicare patients
943
Services billed
1,635

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban181$182,863
XareltoRivaroxaban55$47,587
JardianceEmpagliflozin49$33,335
EntrestoSacubitril/Valsartan39$31,990
Repatha SureclickEvolocumab17$16,449
VascepaIcosapent Ethyl31$15,600
Flecainide Acetate33$1,416
Valsartan20$1,296
Metoprolol Succinate127$998
Rosuvastatin Calcium69$696
Carvedilol43$425
Diltiazem 24hr Er (Cd)Diltiazem Hcl19$412
Atorvastatin Calcium40$323
Amlodipine Besylate63$319
ClopidogrelClopidogrel Bisulfate28$272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$287$182,863181 claims
Boehringer IngelheimJardiance$631$33,33549 claims
NovartisEntresto$507$31,99039 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Boynton Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →